BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 31711714)

  • 1. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics.
    Geeurickx E; Hendrix A
    Mol Aspects Med; 2020 Apr; 72():100828. PubMed ID: 31711714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsy: General Concepts.
    Poulet G; Massias J; Taly V
    Acta Cytol; 2019; 63(6):449-455. PubMed ID: 31091522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of circulating biomarkers in liquid biopsy diagnostics.
    Yeo JC; Lim CT
    Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
    [No Abstract]   [Full Text] [Related]  

  • 4. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Free DNA: Applications in Different Diseases.
    Ranucci R
    Methods Mol Biol; 2019; 1909():3-12. PubMed ID: 30580419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
    Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
    Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy: Current Status and Future Perspectives.
    Mader S; Pantel K
    Oncol Res Treat; 2017; 40(7-8):404-408. PubMed ID: 28693023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized (Pre) Analytical Conditions and Workflow for Droplet Digital PCR Analysis of Cell-Free DNA from Patients with Suspected Lung Carcinoma.
    de Kock R; Deiman B; Kraaijvanger R; Scharnhorst V
    J Mol Diagn; 2019 Sep; 21(5):895-902. PubMed ID: 31229652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preanalytical variables that affect the outcome of cell-free DNA measurements.
    Ungerer V; Bronkhorst AJ; Holdenrieder S
    Crit Rev Clin Lab Sci; 2020 Nov; 57(7):484-507. PubMed ID: 32393081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid Biopsy in Solid Malignancy.
    Scarlotta M; Simsek C; Kim AK
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
    Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
    Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep cfDNA fragment end profiling enables cancer detection.
    Zhitnyuk YV; Koval AP; Alferov AA; Shtykova YA; Mamedov IZ; Kushlinskii NE; Chudakov DM; Shcherbo DS
    Mol Cancer; 2022 Jan; 21(1):26. PubMed ID: 35062943
    [No Abstract]   [Full Text] [Related]  

  • 17. Urine-Based Liquid Biopsy for Nonurological Cancers.
    Jain S; Lin SY; Song W; Su YH
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsy: A New Tool in Oncology.
    Costa JL; Schmitt FC
    Acta Cytol; 2019; 63(6):448. PubMed ID: 31266005
    [No Abstract]   [Full Text] [Related]  

  • 19. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.